Categories: Material Information

GLAXO responds to drug court Rawalpindi judgment

In a notification sent to PSX on 24/04/2024, GlaxoSmithKline Pakistan Limited (GLAXO) has announced its legal position on the GLAXO drug case judgment.

We would like to inform you that the Drug Court Rawalpindi has passed judgement dated April 22, 2024, in Case Judicial No. 4229/DC/Rwp/22 against the current and former officers of GSK under the Drugs Act 1976 related to the provision of sub-standard drugs.

GSK as well as the officers impleaded in the proceedings hereby deny any sort of wrong doing in the matter and are taking immediate steps to challenge the aforementioned judgment before the appellate forum. We would also like to inform you that GSK will keep all stakeholders abreast of any significant updates in this regard.

The shares of GLAXO were last trading at Rs. 98.89 today.

Aamir Hayat

Recent Posts

Impact of JAC T9 Hunter on GAL stock

Ghandhara Automobil;es Limited's (GAL) strategic entry into the pickup truck market with the launch of…

22 hours ago

Is a 100 bps cut likely at the Jan 27 monetary policy meeting?

Topline Securities (Private) Limited has just published a report on the SBP monetary policy update.

6 days ago

MTL gained 20% in one month, here’s why

Taurus Securities Limited has just published a report on MLT's monthly sales.

6 days ago

What to expect from APL Q2 earnings

AKD Securities has just published a report on APL's Q2 earnings expectations. The firm expects…

6 days ago

What to expect from Pakistan State Oil (PSO) Q2 earnings

AKD Securities has just published a report on PSO's Q2 earnings expectations. The firm expects…

7 days ago

Is Engro Fertilizer (EFERT) a good investment for 2025?

Engro Fertilizers (EFERT) having an effective market position as Pakistan’s second largest urea producer has…

2 weeks ago